BioNTech Acquires Biotheus for $950 Million, Targets PD-L1 and VEGF-A in Oncology

BioNTech's strategic acquisition of Biotheus represents a significant move in the oncology sector, securing full ownership of the bispecific antibody BNT327/PM8002, which targets the PD-L1 and VEGF-A pathways. The deal, amounting to $950 million, involves an $800 million upfront payment with potential milestone payments up to $150 million[1][2]. This acquisition aims to enhance cancer treatment by focusing on the immuno-oncology market through a drug design that activates T cells and inhibits tumor growth[1][3]. With this purchase, BioNTech is positioning itself to potentially challenge traditional checkpoint inhibitors like Merck's Keytruda, expand its research and development capabilities in China, and initiate multiple registrational trials targeting various solid tumors[2].